Clinical experience of cancer immunotherapy integrated with Oleic Acid complexed with de-glycosylated vitamin D binding protein

American Journal of Immunology

Volumn 10, Issue 1, 2014, Pages 23-32

  Ward, Emma ^a   Smith, Rodney ^a   Branca, Jacopo J V ^b   Noakes, David ^c   Morucci, Gabriele ^b   Thyer, Lynda ^a  

^a Macro Innovations Ltd   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Immuno Biotech Ltd   (United Kingdom)

Author keywords

Advanced cancer; GcMAF; Integrative immunotherapy; Oleic acid; Ultrasonography

Indexed keywords

ACETYLSALICYLIC ACID; MACROPHAGE ACTIVATING FACTOR; OLEIC ACID; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CARCINOMATOSIS; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER FLOWMETRY; ECHOGRAPHY; FEMALE; HEMATOPOIESIS; HUMAN; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LOW DRUG DOSE; MACROPHAGE ACTIVATION; MALE; MELANOMA METASTASIS; METASTASIS; MIDDLE AGED; MONOCYTE; MULTIPLE MYELOMA; NEBULIZATION; NEOPLASM; POLYACRYLAMIDE GEL ELECTROPHORESIS; SPLEEN BLOOD FLOW; THYROID CANCER; WESTERN BLOTTING;

EID: 84896298849     PISSN: 1553619X     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajisp.2014.23.32     Document Type: Article

References (42)

1. Artym, J. and M. Zimecki, 2013. Milk-derived proteins and peptides in clinical trials. Poste{ogonek}py Hig. Med. Dośw., 67: 800-816. PMID: 24018446
2. Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem., 72: 248-254. DOI: 10.1016/0003-2697(76)90527-3
3. Bradstreet, J.J., E. Vogelaar and L. Thyer, 2012. Initial observations of elevated alpha-Nacetylgalactosaminidase activity associated with autism and observed reductions from gc proteinmacrophage activating factor injections. Autism Insights, 4: 31-38. DOI: 10.4137/AUI.S10485
4. Cokić, V.P. and A.N. Schechter, 2008. Chapter 7 effects of nitric oxide on red blood cell development and phenotype. Curr. Top. Dev. Biol., 82: 169-215. DOI: 10.1016/S0070-2153(07)00007-5
5. Cui, C.Y., W.L. Lu, L. Xiao, S.Q. Zhang and Y.B. Huang et al., 2005. Sublingual delivery of insulin: effects of enhancers on the mucosal lipid fluidity and protein conformation, transport and in vivo hypoglycemic activity. Biol. Pharmaceutical Bull., 28: 2279-2288. DOI: 10.1248/bpb.28.2279
6. Den Hollander, P., M.I. Savage and P.H. Brown, 2013. Targeted therapy for breast cancer prevention. Frontiers Oncol., 3: 250. DOI: 10.3389/fonc.2013.00250
7. Fabris, A., P. Biagioni, T. Punzi, G. Morucci and M. Gulisano et al., 2012. Role of angiotensinconverting enzyme and vitamin D receptor gene polymorphisms in cancer anorexia-cachexia syndrome. Am. J. Immunol., 8: 65-70. DOI: 10.3844/ajisp.2012.65.70
8. Fang, B., M. Zhang, M. Tian, L. Jiang and H.Y. Guo et al., 2013. Bovine lactoferrin binds oleic acid to form an anti-tumor complex similar to HAMLET. Biochim. Biophys. Acta., 1841: 535-543. PMID: 24368211
9. Goto, S., M. Kawata, T. Suzuki, N.S. Kim and C. Ito, 1991. Preparation and evaluation of Eudragit gels. I: Eudragit organogels containing drugs as rectal sustained-release preparations. J. Pharmaceutical Sci., 80: 958-961. DOI: 10.1002/jps.2600801011
10. Gregory, K.J., B. Zhao, D.R. Bielenberg, S. Dridi and J. Wu et al., 2010. Vitamin D binding proteinmacrophage activating factor directly inhibits proliferation, migration and uPAR expression of prostate cancer cells. PLoS One, 5: e13428. DOI: 10.1371/journal.pone.0013428
11. Guinebretière, J.M., E. Menet, A. Tardivon, P. Cherel and D. Vanel, 2005. Normal and pathological breast, the histological basis. Eur. J. Radiol., 54: 6-14. DOI: 10.1016/j.ejrad.2004.11.020
12. Hiroi, M., Y. Sakaeda, H. Yamaguchi and Y. Ohmori, 2013. Anti-inflammatory cytokine interleukin-4 inhibits inducible nitric oxide synthase gene expression in the mouse macrophage cell line RAW264.7 through the repression of octamerdependent transcription. Mediators Inflamm., Epub 2013: 369-693. DOI: 10.1155/2013/369693
13. Ho, C.S.J., A. Rydström, M. Trulsson, J. Bålfors and P. Storm et al., 2012. HAMLET: Functional properties and therapeutic potential. Future Oncol., 8: 1301-1313. DOI: 10.2217/fon.12.122
14. Ho, V.W., K. Leung, A. Hsu, B. Luk and J. Lai et al., 2011. A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res., 71: 4484-4493. DOI: 10.1158/0008-5472.CAN-10-3973
15. Hoque, M., S. Dave, P. Gupta and M. Saleemuddin, 2013. Oleic acid may be the key contributor in the BAMLET-induced erythrocyte hemolysis and tumoricidal action. PLoS One, 8: e68390. DOI: 10.1371/journal.pone.0068390
16. Inui, T., D. Kuchiike, K. Kubo, M. Mette and Y. Uto et al., 2013. Clinical experience of integrative cancer immunotherapy with GcMAF. Anticancer Res., 33: 2917-2919. PMID: 23780980
17. Iversen, P.O., G. Nicolaysen and H.B. Benestad, 1994. Endogenous nitric oxide causes vasodilation in rat bone marrow, bone and spleen during accelerated hematopoiesis. Exp. Hematol., 22: 1297-1302. PMID: 7957715
18. Knyazeva, E.L., V.M. Grishchenko, R.S. Fadeev, V.S. Akatov and S.E. Permyakov et al., 2008. Who is Mr. HAMLET? Interaction of human alphalactalbumin with monomeric oleic acid. Biochemistry, 47: 13127-13137. DOI: 10.1021/bi801423s
19. Lu, H.T., R.N. Chen, M.T. Sheu, C.C. Chang and P.Y. Chou et al., 2011. Rapid-onset sildenafil nasal spray carried by microemulsion systems: In vitro evaluation and in vivo pharmacokinetic studies in rabbits. Xenobiotica, 41: 567-577. DOI: 10.3109/00498254.2011.563877
20. Lucà-Moretti, M., A. Grandi, E. Lucà, G. Muratori and M.G. Nofroni et al., 2003. Master Amino acid Pattern as substitute for dietary proteins during a weight-loss diet to achieve the body's nitrogen balance equilibrium with essentially no calories. Adv. Therapy, 20: 282-291. DOI: 10.1007/BF02849857
21. Nathan, C.F. and J.B. Hibbs, 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Current Opin. Immunol., 3: 65-70. DOI: 10.1016/0952-7915(91)90079-G
22. Nemashkalova, E.L., A.S. Kazakov, L.M. Khasanova, E.A. Permyakov and S.E. Permyakov, 2013. Structural characterization of more potent alternatives to HAMLET, a tumoricidal complex of α-lactalbumin and oleic acid. Biochemistry, 52: 6286-6299. DOI: 10.1021/bi400643s
23. Nonaka, K., S. Onizuka, H. Ishibashi, Y. Uto and H. Hori et al., 2012. Vitamin D binding proteinmacrophage activating factor inhibits HCC in SCID mice. J. Surgical Res., 172: 116-122. DOI: 10.1016/j.jss.2010.07.057
24. Pacini, S., G. Morucci, T. Punzi, M. Gulisano and M. Ruggiero, 2011. Gc protein-derived Macrophage-Activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay. Cancer Immunol. Immunotherapy, 60: 479-485. DOI: 10.1007/s00262-010-0953-7
25. Pacini, S., T. Punzi, G. Morucci, M. Gulisano and M. Ruggiero, 2012. Effects of vitamin d-binding proteinderived macrophage-activating factor on human breast cancer cells. Anticancer Res., 32: 45-52. PMID: 22213287
26. Partridge, S.C., J.E. Gibbs, Y. Lu, L.J. Esserman and D. Tripathy et al., 2005. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR. Am. J. Roentgenol., 184: 1774-1781. DOI: 10.2214/ajr.184.6.01841774
27. Puthia, M., P. Storm, A. Nadeem, S. Hsiung and C. Svanborg, 2014. Prevention and treatment of colon cancer by peroral administration of HAMLET (human α-lactalbumin made lethal to tumour cells). Gut, 63: 131-142. DOI: 10.1136/gutjnl-2012-303715
28. Ruggiero, M. and S. Pacini, 2011. The vitamin D axis in chronic kidney disease-state of the art and future perspectives. Eur. Nephrol., 5: 15-19.
29. Sakata, O., Y. Machida and H. Onishi, 2011. Semi-solid dosage form of clonazepam for rapid oral mucosal absorption. Drug Dev. Ind. Pharm., 37: 809-814. DOI: 10.3109/03639045.2010.545069
30. Smith, K., 2013. Therapy: HAMLET takes a leading role on the colorectal cancer stage. Nat. Rev. Gastroenterol. Hepatol., 10: 126. DOI: 10.1038/nrgastro.2013.27
31. Smith, R., L. Thyer, E. Ward, E. Meacci and J.J.V. Branca et al., 2013. Effects of Gc-macrophage activating factor in human neurons; implications for treatment of chronic fatigue syndrome. Am. J. Immunol., 9: 120-129. DOI: 10.3844/ajisp.2013.120.129
32. Stuehr, D.J. and C.F. Nathan, 1989. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med., 169: 1543-1555. DOI: 10.1084/jem.169.5.1543
33. Thorat, M.A. and J. Cuzick, 2013. Role of aspirin in cancer prevention. Current Oncol. Reports, 15: 533-540. DOI: 10.1007/s11912-013-0351-3
34. Thun, M.J., E.J. Jacobs and C. Patrono, 2012. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol., 9: 259-267. DOI: 10.1038/nrclinonc.2011.199
35. Thyer, L., E. Ward, R. Smith, J.J. Branca and G. Morucci et al., 2013a. GC protein-derived macrophage-activating factor decreases α-Nacetylgalactosaminidase levels in advanced cancer patients. Oncoimmunology, 2: e25769-25775. DOI: 10.4161/onci.25769
36. Thyer, L., E. Ward, R. Smith, J.J.V. Branca and G. Morucci et al., 2013b. Therapeutic effects of highly purified de-glycosylated GcMAF in the immunotherapy of patients with chronic diseases. Am. J. Immunol., 9: 78-84. DOI: 10.3844/ajisp.2013.78.84
37. Thyer, L., E. Ward, R. Smith, M.G. Fiore and S. Magherini et al., 2013c. A Novel role for a major component of the vitamin D axis: Vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages. Nutrients, 5: 2577-2589. DOI: 10.3390/nu5072577
38. Vogel, H.J., 2012. Lactoferrin, a bird's eye view. Biochem. Cell Biol., 90: 233-244. DOI: 10.1139/o2012-016
39. Yamamoto, N. and V.R. Naraparaju, 1998. Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization. Immunol. Cell Biol., 76: 237-244. DOI: 10.1046/j.1440-1711.1998.00748.x
40. Yamamoto, N., H. Suyama, N. Yamamoto and N. Ushijima, 2008a. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived Macrophage Activating Factor (GcMAF). Int. J. Cancer, 122: 461-467. DOI: 10.1002/ijc.23107
41. Yamamoto, N., H. Suyama and N. Yamamoto, 2008b. Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Translat. Oncol., 1: 65-72. DOI: 10.1593/tlo.08106
42. Yamamoto, N., H. Suyama, H. Nakazato, N. Yamamoto and Y. Koga, 2008c. Immunotherapy of metastatic colorectal cancer with vitamin D-binding proteinderived macrophage-activating factor, GcMAF. Cancer Immunol. Immunotherapy, 57: 1007-1016. DOI: 10.1007/s00262-007-0431-z